Annis Gardner Whiting Capital Advisors’s Cytokinetics CYTK Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17	Closed	-$1.12K	–	550
2026 Q1	$1.12K	Sell	17 -11	-39%	-$699	﹤0.01%	1135
2025 Q4	$1.78K	Sell	28 -45	-62%	-$2.8K	﹤0.01%	971
2025 Q3	$4.01K	Hold	73	–	–	﹤0.01%	813
2025 Q2	$2.41K	Hold	73	–	–	﹤0.01%	931
2025 Q1	$2.93K	Hold	73	–	–	﹤0.01%	665
2024 Q4	$3.43K	Hold	73	–	–	﹤0.01%	644
2024 Q3	$3.85K	Hold	73	–	–	﹤0.01%	660
2024 Q2	$3.96K	Hold	73	–	–	﹤0.01%	799
2024 Q1	$5.12K	Hold	73	–	–	﹤0.01%	759
2023 Q4	$6.09K	Hold	73	–	–	﹤0.01%	522
2023 Q3	$2.15K	Buy	+73	New	+$2.43K	﹤0.01%	611

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's CYTK Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 17 shares — an estimated $1.12K sold.

Annis Gardner Whiting Capital Advisors first reported a position in CYTK in Q3 2023 and held it in 11 quarters. The position peaked at $6.09K in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Annis Gardner Whiting Capital Advisors reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Annis Gardner Whiting Capital Advisors sold 17 Cytokinetics shares in Q2 2026, an estimated $1.12K.
Annis Gardner Whiting Capital Advisors first reported a position in Cytokinetics in Q3 2023 and held it in 11 quarters.
Annis Gardner Whiting Capital Advisors's Cytokinetics position peaked at $6.09K in Q4 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.